

Optimized *Patency*
for Your *Portal Hypertension* Patients



PERFORMANCE through data


As the *only* covered stent that is indicated for Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation and revision, the GORE VIATORR® Device has revolutionized TIPS procedures — and optimized primary patency rates in the process.



VIATORR®

TIPS ENDOPROSTHESIS

Superior TIPS Performance



► Demonstrated Track Record

For your patients with portal hypertension, the GORE VIATORR® TIPS Endoprosthesis maintains significantly increased patency compared to bare metal stent alternatives. Highly effective in lowering portal pressure gradients in patients with refractory ascites and variceal bleeding, the GORE VIATORR® TIPS Endoprosthesis effectively treats patients over a longer period of time.

Two clinical studies were conducted in the United States to evaluate the GORE VIATORR® TIPS Endoprosthesis for use in *de novo* TIPS and TIPS revision. These studies demonstrated that primary patency of the GORE VIATORR® Device group was superior to that of the WALLSTENT® Device group ($p < 0.001$) at six months, with no significant differences in mortality or risk of encephalopathy*. Independent research since commercialization has yielded results that complement these original studies**.

The following quotes from leading physicians were taken from a selection of scientific literature that discusses the value of the GORE VIATORR® TIPS Endoprosthesis:

"...the improvement of TIPS patency by using e-PTFE-covered stents is maintained over time with a decreased risk of encephalopathy, while the risk of death is not increased."

Bureau C, Garcia-Pagan JC,
Layrargues GP, Metivier S, Bellot P,
Perreault P, Otal P, Abralde J-G,
Peron JM, Rousseau H, Bosch J, Vinel JP]


"... our large study comparing the [GORE VIATORR® TIPS Endoprosthesis] polytetrafluoroethylene-covered stent with uncovered stents revealed better shunt patency, lower rates of variceal rebleeding and hepatic encephalopathy with the [GORE VIATORR® TIPS Endoprosthesis]."

Tripathi D, Ferguson J, Barkell H,
Macbeth K, Ireland H, Redhead D, Hayes P

Bureau C, Garcia-Pagan JC, Layrargues GP, Metivier S, Bellot P, Perreault P, Otal P, Abralde J-G, Peron JM, Rousseau H, Bosch J, Vinel JP. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: longterm results of a randomized multicentre study *Liver International* 2007 DOI:10.1111/j.1478-3231.2007.01522.x

Tripathi D, Ferguson J, Barkell H, Macbeth K, Ireland H, Redhead D, Hayes P. Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene covered stents *European Journal of Gastroenterology & Hepatology* 2006; 18:225-232

► Primary Patency**



Now you can refer with complete confidence. For the interventional radiologists in your area who treat portal hypertension using the GORE VIATORR® TIPS Endoprosthesis, please visit: goremedical.com/TIPS-MD

*On file with Gore PMA P040027
**Data on file



W. L. GORE & ASSOCIATES, INC.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com

Indications for Use: The GORE VIATORR® TIPS Endoprosthesis is indicated for use in the *de novo* and revision treatment of portal hypertension and its complications such as variceal bleeding, gastropathy, refractory ascites, and / or hepatic hydrothorax. Refer to *Instructions for Use* at goremedical.com for a complete description of all contraindications, warnings, precautions and adverse events. Only

Products listed may not be available in all markets.
GORE, VIATORR®, and designs are trademarks of W. L. Gore & Associates.
WALLSTENT® is a trademark of Boston Scientific Corporation.
©2009 W. L. Gore & Associates, Inc. AN0784-EN1 AUGUST 2009